TNGX: Tango Pharma Net earnings per share (EPS TTM)
Tango Therapeutics (TNGX) is competing for leadership in cancer immunotherapy, a field where the risk of development obsolescence is extremely high. The venture model of Tango Therapeutics (TNGX) involves massive expenditures on genomics in pursuit of future superprofits from patents. Alliances with pharma behemoths are driving growth. The net income per share over the last 12 months on the GURU.Markets system summary chart demonstrates volatility, where -1.36 is recorded as the baseline value.
Summary analytical data breakdowns for Tango Therapeutics Corp (TNGX)
- share price and expert price forecast:
- market capitalization information:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Tango Therapeutics|TNGX - Long-Term Debt to Capital|Short-Term Debt to Equity Tango Therapeutics, Inc.|TNGX - Company Aggregate Debt|Debt to Book Capitalization Ratio Tango Therapeutics, Inc.|TNGX - Long-Term Debt|Company Current Liabilities Tango Therapeutics|Quick Liquidity Indicator tangotx.com
- earnings and multiples data:
TNGX - Profit After Payment of Taxes|Projected Future Earnings Tango Therapeutics|TNGX - Company Value to Net Income|Forward P/E Multiple tangotx.com|TNGX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tango Therapeutics Corp|TNGX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Tango Therapeutics|TNGX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months tangotx.com|TNGX - Earnings per share trend in current year|Expected earnings per share growth for next year Tango Therapeutics
- revenue and sales details:
Fundamental valuation:TNGX - Tango Therapeutics Corp
This indicator measures overall business efficiency by allocating total annual net income per common share to assess the actual return on equity. Analyzing annual net income per share allows for an evaluation of the financial stability of Tango Therapeutics (TNGX), where cost optimization through the outsourcing of clinical trials directly impacts the company's final margins and capitalization rates.
Main competitors
IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months iovance.com (IOVA)|Earnings per share for the last twelve months Immatics NV (IMTX)|Net earnings per share for the last 12 months Xencor Corp XNCR|Compass Therapeutics Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Replimune Inc. REPL|LYEL - Earnings per share for the last twelve months|IPHA (innate-pharma.com) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen Ltd. (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma, Inc.)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)
